基孔肯雅病毒的全灭活疫苗和病毒样颗粒疫苗策略
Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.
作者信息
DeZure Adam D, Berkowitz Nina M, Graham Barney S, Ledgerwood Julie E
机构信息
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
出版信息
J Infect Dis. 2016 Dec 15;214(suppl 5):S497-S499. doi: 10.1093/infdis/jiw352.
Abstract
Chikungunya virus (CHIKV) is a global public health threat, having been identified in >60 countries in Asia, Africa, Europe, and the Americas. There is no cure for or licensed vaccine against CHIKV infection. Initial attempts at CHIKV vaccine development began in the early 1960s. Whole-inactivated and virus-like particle (VLP) vaccines are 2 of the current approaches being evaluated. Success of these approaches is dependent on a safe, well-tolerated vaccine that is immunogenic and deployable in regard to manufacturing, stability, and delivery characteristics.
摘要
基孔肯雅病毒（CHIKV）是一种全球公共卫生威胁，已在亚洲、非洲、欧洲和美洲的60多个国家被发现。目前尚无针对CHIKV感染的治愈方法或获批疫苗。CHIKV疫苗研发的最初尝试始于20世纪60年代初。全灭活疫苗和病毒样颗粒（VLP）疫苗是目前正在评估的两种方法。这些方法的成功取决于一种安全、耐受性良好、具有免疫原性且在生产、稳定性和递送特性方面可部署的疫苗。
相似文献
1
Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.基孔肯雅病毒的全灭活疫苗和病毒样颗粒疫苗策略
J Infect Dis. 2016 Dec 15;214(suppl 5):S497-S499. doi: 10.1093/infdis/jiw352.
2
Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice.二价嵌合病毒样颗粒和 DNA 疫苗共免疫诱导小鼠产生有前景的体液免疫应答。
Front Immunol. 2021 Mar 24;12:655743. doi: 10.3389/fimmu.2021.655743. eCollection 2021.
3
Chikungunya virus vaccines: Current strategies and prospects for developing plant-made vaccines.基孔肯雅病毒疫苗：开发植物源疫苗的当前策略与前景
Vaccine. 2015 Jul 17;33(31):3650-8. doi: 10.1016/j.vaccine.2015.05.104. Epub 2015 Jun 12.
4
A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes.一种病毒样颗粒疫苗在人体内引发针对所有基孔肯雅病毒基因型的广泛中和抗体反应。
J Infect Dis. 2016 Nov 15;214(10):1487-1491. doi: 10.1093/infdis/jiw431. Epub 2016 Sep 21.
5
Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial.一种基孔肯雅病毒样颗粒疫苗的安全性和耐受性结果：一项随机临床试验。
JAMA. 2020 Apr 14;323(14):1369-1377. doi: 10.1001/jama.2020.2477.
6
A chikungunya fever vaccine utilizing an insect-specific virus platform.一种利用昆虫特异性病毒平台的基孔肯雅热疫苗。
Nat Med. 2017 Feb;23(2):192-199. doi: 10.1038/nm.4253. Epub 2016 Dec 19.
7
Development of Vaccines for Chikungunya Fever.基孔肯雅热疫苗的研发
J Infect Dis. 2016 Dec 15;214(suppl 5):S488-S496. doi: 10.1093/infdis/jiw271.
8
Do we need a vaccine against chikungunya?我们需要一种针对基孔肯雅热的疫苗吗？
Pathog Glob Health. 2015 Jun;109(4):170-3. doi: 10.1179/2047773215Y.0000000017. Epub 2015 May 14.
9
Chikungunya Virus Vaccines: Viral Vector-Based Approaches.基孔肯雅病毒疫苗：基于病毒载体的方法。
J Infect Dis. 2016 Dec 15;214(suppl 5):S500-S505. doi: 10.1093/infdis/jiw369.
10
Vaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice.接种基孔肯雅病毒样颗粒疫苗会使老年小鼠的病情恶化。
PLoS Negl Trop Dis. 2019 Apr 26;13(4):e0007316. doi: 10.1371/journal.pntd.0007316. eCollection 2019 Apr.
引用本文的文献
1
Virus-like particle vaccines with epitopes from porcine epidemic virus and transmissible gastroenteritis virus incorporated into self-assembling ADDomer platform provide clinical immune responses in piglets.含有猪流行性腹泻病毒和传染性胃肠炎病毒表位的类病毒颗粒疫苗与自组装 ADDomer 平台结合，为仔猪提供临床免疫应答。
Front Immunol. 2023 Oct 24;14:1251001. doi: 10.3389/fimmu.2023.1251001. eCollection 2023.
2
Equine Polyclonal Antibodies Prevent Acute Chikungunya Virus Infection in Mice.马多克隆抗体可预防小鼠感染急性基孔肯雅病毒。
Viruses. 2023 Jun 29;15(7):1479. doi: 10.3390/v15071479.
3
Evolution and immunopathology of chikungunya virus informs therapeutic development.基孔肯雅热病毒的进化和免疫病理学为治疗方法的开发提供了信息。
Dis Model Mech. 2023 Apr 1;16(4). doi: 10.1242/dmm.049804. Epub 2023 Apr 4.
4
Efficacy and safety of COVID-19 vaccines.新型冠状病毒疫苗的有效性和安全性。
Cochrane Database Syst Rev. 2022 Dec 7;12(12):CD015477. doi: 10.1002/14651858.CD015477.
5
Comparing the Immunogenicity and Protective Effects of Three MERS-CoV Inactivation Methods in Mice.比较三种中东呼吸综合征冠状病毒灭活方法在小鼠体内的免疫原性和保护作用。
Vaccines (Basel). 2022 Oct 31;10(11):1843. doi: 10.3390/vaccines10111843.
6
An mRNA vaccine encoding Chikungunya virus E2-E1 protein elicits robust neutralizing antibody responses and CTL immune responses.一种编码基孔肯雅病毒 E2-E1 蛋白的 mRNA 疫苗可引发强烈的中和抗体反应和 CTL 免疫反应。
Virol Sin. 2022 Apr;37(2):266-276. doi: 10.1016/j.virs.2022.01.032. Epub 2022 Jan 28.
7
Development and Application of a Reverse-Transcription Recombinase-Aided Amplification Assay for Porcine Epidemic Diarrhea Virus.猪流行性腹泻病毒逆转录重组酶介导等温扩增检测方法的建立与应用
Viruses. 2022 Mar 12;14(3):591. doi: 10.3390/v14030591.
8
Expression and immunogenicity of nsp10 protein of porcine epidemic diarrhea virus.猪流行性腹泻病毒 nsp10 蛋白的表达及其免疫原性。
Res Vet Sci. 2022 May;144:34-43. doi: 10.1016/j.rvsc.2021.12.024. Epub 2022 Jan 3.
9
Porcine epidemic diarrhea virus: Molecular mechanisms of attenuation and vaccines.猪流行性腹泻病毒：减毒机制与疫苗。
Microb Pathog. 2020 Dec;149:104553. doi: 10.1016/j.micpath.2020.104553. Epub 2020 Oct 1.
10
Novel insights into the treatment of SARS-CoV-2 infection: An overview of current clinical trials.新型冠状病毒感染治疗的新视角：当前临床试验概述。
Int J Biol Macromol. 2020 Dec 15;165(Pt A):18-43. doi: 10.1016/j.ijbiomac.2020.09.204. Epub 2020 Sep 28.
本文引用的文献
1
Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.rVSV- 载体疫苗表达埃博拉表面糖蛋白的功效和效果：来自几内亚环疫苗接种群组随机对照试验的中期结果。
Lancet. 2015 Aug 29;386(9996):857-66. doi: 10.1016/S0140-6736(15)61117-5. Epub 2015 Aug 3.
2
High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines.菲律宾一个前瞻性队列中基孔肯雅病毒亚临床感染的高发生率及中和抗体与保护作用的关联。
PLoS Negl Trop Dis. 2015 May 7;9(5):e0003764. doi: 10.1371/journal.pntd.0003764. eCollection 2015 May.
3
Chikungunya virus and the global spread of a mosquito-borne disease.基孔肯雅病毒与一种蚊媒疾病的全球传播
N Engl J Med. 2015 Mar 26;372(13):1231-9. doi: 10.1056/NEJMra1406035.
4
Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.基于重组麻疹病毒的基孔肯雅疫苗的免疫原性、安全性和耐受性：一项随机、双盲、安慰剂对照、活性对照、首次人体试验。
Lancet Infect Dis. 2015 May;15(5):519-27. doi: 10.1016/S1473-3099(15)70043-5. Epub 2015 Mar 2.
5
An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trial.在一项随机3期试验中，一种灭活的罗斯河病毒疫苗在成年人群中耐受性良好且具有免疫原性。
Clin Vaccine Immunol. 2015 Mar;22(3):267-73. doi: 10.1128/CVI.00546-14. Epub 2014 Dec 24.
6
Prime-boost immunization strategies against Chikungunya virus.针对基孔肯雅病毒的初免-加强免疫策略。
J Virol. 2014 Nov;88(22):13333-43. doi: 10.1128/JVI.01926-14. Epub 2014 Sep 10.
7
Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial.在健康成年人中，基孔肯雅病毒样颗粒疫苗的安全性和耐受性：一项 1 期剂量递增试验。
Lancet. 2014 Dec 6;384(9959):2046-52. doi: 10.1016/S0140-6736(14)61185-5. Epub 2014 Aug 14.
8
Reemergence of chikungunya virus.基孔肯雅病毒的再次出现。
J Virol. 2014 Oct;88(20):11644-7. doi: 10.1128/JVI.01432-14. Epub 2014 Jul 30.
9
A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.一种新型基于痘病毒的疫苗，MVA-CHIKV，具有高度的免疫原性，可保护小鼠免受基孔肯雅热感染。
J Virol. 2014 Mar;88(6):3527-47. doi: 10.1128/JVI.03418-13. Epub 2014 Jan 8.
10
Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose.基孔肯雅热候选疫苗高度减毒，可在单次接种后保护非人类灵长类动物免受遥测监测疾病的侵害。
J Infect Dis. 2014 Jun 15;209(12):1891-9. doi: 10.1093/infdis/jiu014. Epub 2014 Jan 7.
Zotero 插件